Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models
Annals of the Rheumatic Diseases · 2025-12 · 84 (12) · 2049-2064
DOI: 10.1016/j.ard.2025.08.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025-12. Verfasst von Léa Debrut und 13 weiteren Autor:innen. Beteiligte Einrichtung: UR3072 Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg, France; Université de Strasbourg, CNRS, Inserm, IGBMC UMR 7104-UMR-S…. Hauptthemen laut MEDLINE: Dermatomyositis, Proteasome Endopeptidase Complex, Muscle Fibers, Skeletal, Proteasome Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Société Française de Rhumatologie, AFM-Téléthon.
Abstract (Originalsprache)
OBJECTIVES: This study aims to characterise the molecular pathways underpinning perifascicular muscle fibre alterations to identify repositionable molecules for dermatomyositis (DM) treatment, and validate potential candidates in preclinical models. METHODS: RNA-sequencing was performed to determine the transcriptome of microdissected peri- and endofascicular myofibres from 7 patients with untreated and early DM (symptoms
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UR3072 Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg, France; Université de Strasbourg, CNRS, Inserm, IGBMC UMR 7104-UMR-S 1258, Illkirch, France.
- UR3072 Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg, France; Explorations Fonctionnelles Musculaires, Service de Physiologie, Centre de Référence des Maladies Autoimmunes Rares, Hôpitaux Univ…
- UR3072 Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg, France.
- Clinical Immunology Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
- Université de Strasbourg, CNRS, Inserm, IGBMC UMR 7104-UMR-S 1258, Illkirch, France.
- Département d'Anatomopathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Förderung
- Agence Nationale de la Recherche
- Société Française de Rhumatologie
- AFM-Téléthon
- CSL Behring LLC
Zitieren
APA
Debrut, L., Giannini, M., Quiring, G., Perniola, S., Rovito, D., Keime, C., Lannes, B., Nadaj-Pakleza, A., Chanson, J. B., Charles, A. L., Geny, B., Metzger, D., Laverny, G., & Meyer, A. (2025). Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models. Annals of the Rheumatic Diseases, 84(12), 2049-2064. https://doi.org/10.1016/j.ard.2025.08.031
Vancouver
Debrut L, Giannini M, Quiring G, Perniola S, Rovito D, Keime C, et al. Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models. Annals of the Rheumatic Diseases. 2025;84(12):2049-2064. doi:10.1016/j.ard.2025.08.031
BibTeX
@article{Debrut2025,
author = {Debrut, Léa and Giannini, Margherita and Quiring, Giulia and Perniola, Simone and Rovito, Daniela and Keime, Céline and Lannes, Béatrice and Nadaj-Pakleza, Aleksandra and Chanson, Jean-Baptiste and Charles, Anne-Laure and Geny, Bernard and Metzger, Daniel and Laverny, Gilles and Meyer, Alain},
title = {Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
number = {12},
pages = {2049--2064},
doi = {10.1016/j.ard.2025.08.031}
}
EUVIMED